Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectrum Pharmaceuticals Inc Raises FY 2012 Revenue Guidance

Wednesday, 7 Nov 2012 07:00am EST 

Spectrum Pharmaceuticals Inc announced that it expects pro-forma revenue to exceed $300 million in fiscal 2012, up from earlier guidance of around $300 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $265 million for fiscal 2012. 

Company Quote

-0.13 -1.81%
3:35pm EDT